U.S. regulators launch new review of infant RSV therapies from Merck, Sanofi, and AstraZeneca amid scrutiny by Health Secretary Robert F. Kennedy Jr.
HealthDay News — Federal officials say the US Food and Drug Administration (FDA) is reviewing reports of possible deaths in adults and children following COVID-19 vaccination. Federal officials say ...
HealthDay News — Federal regulators have begun a safety review of two RSV medicines used to protect infants, even though no safety problems have been reported. The review covers Beyfortus (from Sanofi ...
The US Food and Drug Administration (FDA) plans to add a “black box” warning to COVID-19 vaccines, CNN reported, citing two ...
Federal regulators have begun a safety review of two RSV medicines used to protect infants, even though no safety problems ...
Learn about the FDA's review of the safety of RSV prevention drugs Clesrovimab and Nirsevimab for infants and toddlers. Find ...
On the campaign trail last October, President Trump promised to let his health secretary, Robert F. Kennedy Jr., “go wild on ...
FDA turns up the heat: Federal regulators are requesting more safety information from drugmakers on products meant to protect ...
The drugs are essentially laboratory-made versions of natural antibodies that help the immune system fight off RSV. The FDA ...
The FDA has informed Merck, Sanofi and AstraZeneca of the safety investigation into their RSV antibodies, though it remains ...
The Food and Drug Administration has launched a safety review of two approved RSV drugs for infants, the latest immunizations ...
U.S. health regulators informed senior executives at Merck, Sanofi and AstraZeneca last week that their approved protective RSV treatments for infants would face fresh safety scrutiny following ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback